8:00am Morning Coffee & Networking
8:50 am Chairs Opening Remarks
Leveraging AI & Bioinformatics for Faster, More Precise & Cost-Effective Design of Novel Induced Proximity Drugs
9:00 am Deep Dive Workshop: AI-Driven Ternary Complex Prediction & Optimization to Reduce Medicinal Chemistry Burden & Accelerate Induced Proximity Drug Discovery
Synopsis
The design of induced proximity-based drugs requires precise ternary complex formation to achieve optimal target engagement and functional efficacy. Traditionally, medicinal chemistry has relied on brute-force screening, but recent advances in AI-driven modeling and bioinformatics are transforming this process—enabling faster, more accurate, and costeffective drug design.
This session will explore how machine learning and computational modeling can predict stable ternary complexes with greater accuracy, refine protein-protein interaction networks, and integrate experimental data to accelerate drug discovery pipelines. Key considerations include minimizing structural bias, enhancing target selectivity, and optimizing hit-to-lead strategies for novel mechanisms of action.
We will showcase real-world applications of AI and bioinformatics in reducing medicinal chemistry burdens, streamlining lead optimization, and driving the next generation of induced proximity-based drugs.
Key Learning Objectives:
How are AI-driven models evolving beyond traditional screening methods to improve the accuracy of prospectively predicting stable ternary complexes?
How can ML approaches optimize protein-protein interactions to improve ligand design, target selectivity, and functional readouts in induced proximity drug discovery to minimize off-target effects and accelerate clinically viable induced proximity therapeutics?
How does integrating bioinformatics with experimental data reduce structural bias, accelerate validation, and improve hit-to-lead strategies for novel MoAs?
12:00pm Lunch Break & Networking
Bridging Discovery & Clinical Success in Induced Proximity Drug Development to Enhance Safety, Selectivity & Translational Viability for Improved Patient Outcomes
1:00 pm Harnessing Amino Acid-Based Degradation & Protein Stabilization to Expand Induced Proximity Therapeutic Strategies for Increased Clinical Use
Synopsis
- How to leverage amino acid-based degradation signals as an alternative to E3 ligases to enable more precise and tunable protein regulation for therapeutic applications
- How to integrate protein stabilization strategies with induced proximity approaches to prevent misfolding, enhance functional recovery, and address neurodegenerative diseases like Alzheimer’s and ALS
- How to apply induced proximity-driven degradation and stabilization mechanisms to improve drug selectivity, enhance translational viability, and drive clinically meaningful patient outcomes
1:30 pm Targeting the Right Patients: Aligning Mechanism of Action with Disease Biology & Patient Populations to Improve Treatment Precision & Maximize Clinical Impact
Synopsis
- How to leverage genomic/proteomic data in early discovery to ensure induced proximity drug candidates align with clinically relevant patient subpopulations for maximizing therapeutic efficacy?
- How can biomarker-driven patient stratification improve safety profiles to optimize trial design and safeguard regulatory approval in the future?
2:00pm Afternoon Break & Networking
Securing Investment & Partnerships to De-Risk the Discovery Pipeline & Expand the Arsenal of Future Novel Proximity Based Drugs
3:00 pm Roundtable Discussion: Aligning Target Validation Strategies with Investor Requirements to Secure Early Funding for Sustaining Proximity-Based Drug Discovery Programs
Synopsis
- How to position early stage induced proximity programs for successful funding rounds from Venture capital, strategic pharma partnerships and government grants?
- What data do investors want to see at different funding stages, from seed to IPO, to set up for future success?
- How can induced proximity focused biotechs differentiate themselves in an increasingly competitive drug discovery landscape to secure investment?
3:30 pm Panel Discussion: Forging Strategic Pharma & Biotech Collaborations to Accelerate Induced Proximity Success
Synopsis
- What are the key partnership models – licensing, co-development, strategic acquisitions – between big pharma and small biotechs for advancing induced proximity programs effectively?
- How can cost efficient collaborations with academia and CROs help inform start-ups on resource allocation to de-risk induced proximity platforms before major investments?
- How can pioneering biotechs strategically frame their programs as must-have assets to big pharma to secure collaborations to advance novel proximity-based drug candidates?